Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $22.22 Average Target Price from Analysts

Key Points

• Bicycle Therapeutics PLC has received a consensus rating of "Moderate Buy" from ten brokerages, with three suggesting a hold and seven recommending a buy.
• Recent price target adjustments from analysts have varied significantly, with estimates ranging from $10.00 to $44.00, indicating a wide range of opinion on the stock's potential.
• The company reported a loss of $1.14 earnings per share, missing analysts' estimates, and had a revenue of $2.90 million for the quarter, far below the anticipated $9.43 million.

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $22.2222.

BCYC has been the subject of a number of research reports. Oppenheimer reiterated an "outperform" rating and issued a $44.00 price objective (down previously from $48.00) on shares of Bicycle Therapeutics in a report on Monday, August 11th. Royal Bank Of Canada set a $27.00 price target on shares of Bicycle Therapeutics and gave the company an "outperform" rating in a research report on Monday, August 11th. Morgan Stanley dropped their price target on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, August 12th. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Finally, B. Riley decreased their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a report on Friday, May 2nd.

Institutional Trading of Bicycle Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares during the period. Ausdal Financial Partners Inc. bought a new position in shares of Bicycle Therapeutics in the 2nd quarter worth about $70,000. Sei Investments Co. acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at about $74,000. Virtus Investment Advisers LLC lifted its stake in shares of Bicycle Therapeutics by 32.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company's stock valued at $75,000 after purchasing an additional 2,659 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Bicycle Therapeutics by 879.5% during the 1st quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock valued at $76,000 after purchasing an additional 8,065 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Trading Up 0.3%

Shares of NASDAQ BCYC traded up $0.02 during mid-day trading on Friday, hitting $7.12. 233,688 shares of the stock traded hands, compared to its average volume of 265,182. Bicycle Therapeutics has a twelve month low of $6.10 and a twelve month high of $28.67. The firm has a 50 day simple moving average of $7.69 and a two-hundred day simple moving average of $8.54.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.95) by ($0.19). Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.The firm had revenue of $2.90 million during the quarter, compared to analyst estimates of $9.43 million. As a group, sell-side analysts expect that Bicycle Therapeutics will post -3.06 EPS for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.